Format

Send to

Choose Destination
Med Clin North Am. 2018 Jan;102(1):135-148. doi: 10.1016/j.mcna.2017.08.010.

Obesity Pharmacotherapy.

Author information

1
Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, 1165 York Avenue, New York, NY 10065, USA. Electronic address: kph2001@med.cornell.edu.
2
Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, 1165 York Avenue, New York, NY 10065, USA.

Abstract

Although diet, physical activity, and behavioral modifications are the cornerstones of weight management, weight loss achieved by lifestyle modifications alone is often limited and difficult to maintain. Pharmacotherapy for obesity can be considered if patients have a body mass index (BMI) of 30 kg/m2 or greater or BMI of 27 kg/m2 or greater with weight-related comorbidities. The 6 most commonly used antiobesity medications are phentermine, orlistat, phentermine/topiramate extended release, lorcaserin, naltrexone sustained release (SR)/bupropion SR, and liraglutide 3.0 mg. Successful pharmacotherapy for obesity depends on tailoring treatment to patients' behaviors and comorbidities and monitoring of efficacy, safety, and tolerability.

KEYWORDS:

Liraglutide; Lorcaserin; Naltrexone/bupropion; Obesity; Orlistat; Pharmacotherapy; Phentermine/topiramate; Weight management

PMID:
29156182
DOI:
10.1016/j.mcna.2017.08.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center